[Treatment of pseudomonas infection with the new ureidopenicillin, azlocillin (author's transl)].
Azlocillin, in vitro four to eight times more effective against Pseudomonas aeruginosa than carbenicillin, was administered to 30 patients severely ill and having an additional pseudomonas infection. The drug was given at a dose of 4-6 g, in one case 8 g, per day, sometimes together with an aminoglycoside. Treatment was effective in 20, improvement occurred in five and failure only in four. In one instance the effect of the drug could not be evaluated. Results were particularly striking in septicaemia and necrotising external otitis. Pulmonary and wound infections in patients with circulatory disturbances did not respond so well. There were no serious side effects. The drug should not as yet be used at too high a dosage.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010032:Otitis Externa / Q000188:drug therapy; D010406:Penicillins / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy*; D012141:Respiratory Tract Infections / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy; D014946:Wound Infection / Q000188:drug therapy
D010406:Penicillins
Behandlung von Pseudomonas-Infektionen mit dem neuen Ureidopenicillin Azlocillin.